NASDAQ:VTVT vTv Therapeutics (VTVT) Stock Price, News & Analysis $17.29 -0.40 (-2.26%) Closing price 04:00 PM EasternExtended Trading$17.06 -0.23 (-1.33%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About vTv Therapeutics Stock (NASDAQ:VTVT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get vTv Therapeutics alerts:Sign Up Key Stats Today's Range$16.71▼$18.0050-Day Range$17.29▼$33.2952-Week Range$16.71▼$44.00Volume26,819 shsAverage Volume22,303 shsMarket Capitalization$69.33 millionP/E RatioN/ADividend YieldN/APrice Target$55.83Consensus RatingModerate Buy Company Overview vTv Therapeutics is a U.S. clinical-stage biopharmaceutical company that discovers and develops small-molecule medicines for serious diseases. Its research has focused on metabolic conditions and other areas of significant medical need. The company’s candidates have included cadisegliatin, formerly known as TTP399, an oral glucokinase activator studied as an addition to insulin therapy for people with type 1 diabetes, and azeliragon, an investigational compound studied for Alzheimer’s disease. These are development-stage products, not established commercial medicines. Based in High Point, North Carolina, vTv has advanced its candidates through clinical research rather than marketing a broad range of approved products. Paul Sekhri has served as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More vTv Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreVTVT MarketRank™: 2.924015382575 of 5 starsvTv Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 388th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingvTv Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialvTv Therapeutics has a consensus price target of $55.83, representing about 222.9% upside from its current price of $17.29.Amount of Analyst CoveragevTv Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about vTv Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for vTv Therapeutics are expected to decrease in the coming year, from ($2.58) to ($3.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of vTv Therapeutics is -18.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of vTv Therapeutics is -18.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiovTv Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.93% of the float of vTv Therapeutics has been sold short.Short Interest Ratio / Days to CovervTv Therapeutics has a short interest ratio ("days to cover") of 8.21.Change versus previous monthShort interest in vTv Therapeutics has recently increased by 1.41%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldvTv Therapeutics does not currently pay a dividend.Dividend GrowthvTv Therapeutics does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.09 News SentimentvTv Therapeutics has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for vTv Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows4 people have added vTv Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, vTv Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.99% of the stock of vTv Therapeutics is held by insiders.Percentage Held by Institutions17.51% of the stock of vTv Therapeutics is held by institutions.Read more about vTv Therapeutics' insider trading history. Receive VTVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VTVT Stock News HeadlinesComparing vTv Therapeutics (VTVT) and Its RivalsNovember 7, 2026 | americanbankingnews.comvTv Therapeutics (NASDAQ:VTVT) Stock Bumped Up to "Hold" by Wall Street ZenNovember 7, 2026 | americanbankingnews.comThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.November 17 at 1:00 AM | Digest Publishing (Ad)vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 5, 2026 | finance.yahoo.comvTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL ...October 27, 2026 | markets.businessinsider.comvTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery SystemsOctober 27, 2026 | globenewswire.comvTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program TranscriptOctober 20, 2026 | seekingalpha.comvTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026October 10, 2026 | markets.businessinsider.comSee More Headlines VTVT Stock Analysis - Frequently Asked Questions How have VTVT shares performed this year? vTv Therapeutics' stock was trading at $39.99 on January 1st, 2026. Since then, VTVT stock has decreased by 56.8% and is now trading at $17.29. How were vTv Therapeutics' earnings last quarter? vTv Therapeutics Inc. (NASDAQ:VTVT) issued its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.09) by $0.15. When did vTv Therapeutics' stock split? Shares of vTv Therapeutics reverse split on the morning of Tuesday, November 21st 2023.The 1-40 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did vTv Therapeutics IPO? vTv Therapeutics (VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,812,500 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers. Who are vTv Therapeutics' major shareholders? Top institutional shareholders of vTv Therapeutics include Samsara Biocapital LLC (9.00%), Marshall Wace LLP (0.61%), State Street Corp (0.33%) and China Universal Asset Management Co. Ltd.. View institutional ownership trends. How do I buy shares of vTv Therapeutics? Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of vTv Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that vTv Therapeutics investors own include NIO (NIO), Nokia (NOK), Sorrento Therapeutics (SRNE), Tesla (TSLA), Micron Technology (MU), Advanced Micro Devices (AMD) and OPKO Health (OPK). Company Calendar Last Earnings11/05/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, VTVT's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VTVT CIK1641489 Webwww.vtvtherapeutics.com Phone(336) 841-0300Fax336-841-0310Employees26Year Founded1998Price Target and Rating Average Price Target for vTv Therapeutics$55.83 High Price Target$67.00 Low Price Target$42.00 Potential Upside/Downside+222.9%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.97 million Net MarginsN/A Pretax Margin-20.84% Return on Equity-10.15% Return on Assets-8.65% Debt Debt-to-Equity RatioN/A Current Ratio11.19 Quick Ratio11.19 Sales & Book Value Annual Sales$1.02 million Price / Sales67.97 Cash FlowN/A Price / Cash FlowN/A Book Value$17.37 per share Price / Book1.00Miscellaneous Outstanding Shares4,010,000Free Float3,772,000Market Cap$69.33 million OptionableNot Optionable Beta0.28 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:VTVT) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share vTv Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.